ANI Pharmaceuticals vs Prestige Consumer Healthcare
Prestige Consumer Healthcare reported revenue of $1.1 billion in fiscal 2026, 1.2 times ANI Pharmaceuticals' $883 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Prestige Consumer Healthcare's fell 4.3%. ANI Pharmaceuticals had an operating margin of 12.6%, against 28.4% at Prestige Consumer Healthcare. Free cash flow was $171 million at ANI Pharmaceuticals and $246 million at Prestige Consumer Healthcare. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| ANI Pharmaceuticals | Prestige Consumer Healthcare | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $883M | $1.1B |
| Revenue growth | 43.8% | −4.3% |
| Revenue growth a year, last 5 years | 33.5% | 2.9% |
| Gross margin | — | 54.7% |
| Operating margin | 12.6% | 28.4% |
| Net margin | 8.9% | 17.5% |
| Free cash flow | $171M | $246M |
| Free cash flow margin | 19.4% | 22.6% |
| Return on capital | 15.9% | 8.2% |
| Net debt to EBITDA | 0.1x | 2.8x |
| Dividends and buybacks | $13M | $156M |
| Change in diluted share count | 9.9% | −2.7% |
| Last close | $67.41 | $42.98 |
| P/E at the last close | 13.5× | 13.3× |
| Insider trades, last 12 months | sold $15.3 million | sold $424,424 |
| Piotroski F-score | 6 of 8 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
ANI PharmaceuticalsPrestige Consumer Healthcare
Operating margin
Percent of revenue
ANI PharmaceuticalsPrestige Consumer Healthcare
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsPrestige Consumer Healthcare
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Prestige Consumer Healthcare pages.